Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984667 · ClinicalTrials.gov registry record
C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors
A clinical trial of Brain Tumor and Mild Neurocognitive Disorder, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT05984667: Completed study of Brain Tumor and Mild Neurocognitive Disorder, sponsored by Virginia Commonwealth University.
NCT05984667 is a study of Brain Tumor and Mild Neurocognitive Disorder that has completed, run by Virginia Commonwealth University. The registered enrollment target is 32 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05984667, a study of Brain Tumor and Mild Neurocognitive Disorder, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of Phase Ib Trial is to determine the feasibility and acceptability of telehealth C-SMART for patients with primary brain tumor and mild neurocognitive deficits (N=18) and their caregivers (N=14) A subset (n=3) of participants will undergo rs-fMRI both pre- and post-C-SMART to test feasibility of advanced functional imaging in this population.
Primary Outcome
As evidenced by rates of participant screening, eligibility, and consent
Conditions Studied
Interventions
- BEHAVIORAL C-SMART
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2025-07-23 |
What the finished NCT05984667 record still lists
NCT05984667 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which C-SMART is the first listed.
NCT05984667 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05984667 about?
NCT05984667 is a clinical study titled "C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors". The goal of Phase Ib Trial is to determine the feasibility and acceptability of telehealth C-SMART for patients with primary brain tumor and mild neurocognitive deficits (N=18) and their caregivers (N=14) A subset (n=3) of participants will undergo rs-fMRI both pre- and post-C-SMART to test feasibil...
What is the current status of trial NCT05984667?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2023-09-15. Estimated completion is 2025-07-23.
What conditions does trial NCT05984667 study?
This clinical trial studies the following conditions: Brain Tumor, Mild Neurocognitive Disorder, Glioma, Mixed.
What interventions are being tested in trial NCT05984667?
The interventions under investigation include: C-SMART (BEHAVIORAL).
Who is sponsoring clinical trial NCT05984667?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05984667 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05984667's enrollment target sits among peer trials
32 42nd of 69 higher than 26 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI